JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients

The use of Natalizumab in Multiple Sclerosis (MS) can cause the reactivation of the polyomavirus JC (JCPyV); this may result in the development of progressive multifocal leukoencephalopathy (PML), a rare and usually lethal disease. JCPyV infection is highly prevalent in worldwide population, but the...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostini, Simone, Mancuso, Roberta, Costa, Andrea Saul, Caputo, Domenico, Clerici, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000901/
https://www.ncbi.nlm.nih.gov/pubmed/33809082
http://dx.doi.org/10.3390/v13030468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000901/
https://www.ncbi.nlm.nih.gov/pubmed/33809082
http://dx.doi.org/10.3390/v13030468

Ejemplares similares